G A Mashour1, A Ben Abdallah2, K O Pryor3, R El-Gabalawy4, P E Vlisides5, E Jacobsohn6, E Lenze7, H R Maybrier2, R A Veselis8, M S Avidan2. 1. Center for Consciousness Science, Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, MI, USA. Electronic address: gmashour@umich.edu. 2. Department of Anesthesiology, Washington University School of Medicine, Saint Louis, MO, USA. 3. Department of Anesthesiology, Weill Cornell Medicine, New York, NY, USA. 4. Department of Clinical Health Psychology, University of Manitoba, Winnipeg, MB, Canada; Department of Anesthesia and Perioperative Medicine, University of Manitoba, Winnipeg, MB, Canada. 5. Center for Consciousness Science, Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, MI, USA. 6. Department of Anesthesia, University of Manitoba, Winnipeg, MB, Canada; Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada. 7. Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA. 8. Department of Anesthesiology, Weill Cornell Medicine, New York, NY, USA; Department of Neuroanesthesiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
BACKGROUND:Ketamine is a general anaesthetic with anti-depressant effects at subanaesthetic doses. We hypothesised that intraoperative administration of ketamine would prevent or mitigate postoperative depressive symptoms in surgical patients. METHODS: We conducted an international, randomised clinical trial testing the effects of intraoperative administration of ketamine [0.5 mg kg-1 (Lo-K) or 1.0 mg kg-1 (Hi-K)] vs control [saline placebo (P)] in patients≥60 yr old undergoing major surgery with general anaesthesia. We administered the Patient Health Questionnaire-8 before the operation, on postoperative day (POD) 3 (primary outcome), and on POD30 to assess depressive symptoms, a secondary outcome of the original trial. RESULTS: There was no significant difference on POD3 in the proportion of patients with symptoms suggestive of depression between the placebo [23/156 (14.7%)] and combined ketamine (Lo-K plus Hi-K) [61/349 (17.5%)] groups [difference = -2.7%; 95% confidence interval (CI), 5.0% to -9.4%; P=0.446]. Of the total cohort, 9.6% (64/670; 95% CI, 7.6-12.0%) had symptoms suggestive of depression before operation, which increased to 16.6% (84/505; 95% CI, 13.6-20.1%) on POD3, and decreased to 11.9% (47/395; 95% CI, 9.1-15.5%) on POD30. Of the patients with depressive symptoms on POD3 and POD30, 51% and 49%, respectively, had no prior history of depression or depressive symptoms. CONCLUSIONS: Major surgery is associated with new-onset symptoms suggestive of depression in patients ≥60 yr old. Intraoperative administration of subanaesthetic ketamine does not appear to prevent or improve depressive symptoms. CLINICAL TRIALS REGISTRATION: NCT01690988.
RCT Entities:
BACKGROUND:Ketamine is a general anaesthetic with anti-depressant effects at subanaesthetic doses. We hypothesised that intraoperative administration of ketamine would prevent or mitigate postoperative depressive symptoms in surgical patients. METHODS: We conducted an international, randomised clinical trial testing the effects of intraoperative administration of ketamine [0.5 mg kg-1 (Lo-K) or 1.0 mg kg-1 (Hi-K)] vs control [saline placebo (P)] in patients ≥60 yr old undergoing major surgery with general anaesthesia. We administered the Patient Health Questionnaire-8 before the operation, on postoperative day (POD) 3 (primary outcome), and on POD30 to assess depressive symptoms, a secondary outcome of the original trial. RESULTS: There was no significant difference on POD3 in the proportion of patients with symptoms suggestive of depression between the placebo [23/156 (14.7%)] and combined ketamine (Lo-K plus Hi-K) [61/349 (17.5%)] groups [difference = -2.7%; 95% confidence interval (CI), 5.0% to -9.4%; P=0.446]. Of the total cohort, 9.6% (64/670; 95% CI, 7.6-12.0%) had symptoms suggestive of depression before operation, which increased to 16.6% (84/505; 95% CI, 13.6-20.1%) on POD3, and decreased to 11.9% (47/395; 95% CI, 9.1-15.5%) on POD30. Of the patients with depressive symptoms on POD3 and POD30, 51% and 49%, respectively, had no prior history of depression or depressive symptoms. CONCLUSIONS: Major surgery is associated with new-onset symptoms suggestive of depression in patients ≥60 yr old. Intraoperative administration of subanaesthetic ketamine does not appear to prevent or improve depressive symptoms. CLINICAL TRIALS REGISTRATION: NCT01690988.
Authors: Chadi G Abdallah; Thomas G Adams; Benjamin Kelmendi; Irina Esterlis; Gerard Sanacora; John H Krystal Journal: Depress Anxiety Date: 2016-04-06 Impact factor: 6.505
Authors: I Esterlis; N DellaGioia; R H Pietrzak; D Matuskey; N Nabulsi; C G Abdallah; J Yang; C Pittenger; G Sanacora; J H Krystal; R V Parsey; R E Carson; C DeLorenzo Journal: Mol Psychiatry Date: 2017-04-11 Impact factor: 15.992
Authors: R Becker; U Braun; A J Schwarz; N Gass; J I Schweiger; W Weber-Fahr; E Schenker; M Spedding; C Clemm von Hohenberg; C Risterucci; Z Zang; O Grimm; H Tost; A Sartorius; A Meyer-Lindenberg Journal: Transl Psychiatry Date: 2016-04-19 Impact factor: 6.222
Authors: Alexander D Stoker; David M Rosenfeld; Matthew R Buras; Jeremy M Alvord; Andrew W Gorlin Journal: J Pain Res Date: 2019-12-23 Impact factor: 3.133
Authors: Yang Zhou; Bo Ma; Wanchen Sun; Juan Wang; Yuxuan Fu; Anxin Wang; Gang Wang; Ruquan Han Journal: BMJ Open Date: 2022-04-26 Impact factor: 2.692